The in vitro activity of the histatin derivative P-113, alone or combined with eight antibiotics, was investigated against multidrug-resistant strains isolated from clinical specimens of immunocompromised patients with pneumonia. The gram-negative isolates were susceptible to P-113. S. aureus showed less susceptibility. Synergy was demonstrated when P-113 was combined with beta-lactams against gram-negative organisms.
In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients / Giacometti, Andrea; Cirioni, Oscar; Kamysz, W; D'Amato, G; Silvestri, Carmela; Del Prete, Ms; Licci, Alberto; Riva, A; Lukasiak, J; Scalise, Giorgio. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - STAMPA. - 49:3(2005), pp. 1249-1252. [10.1128/AAC.49.3.1249-1252.2005]
In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients.
GIACOMETTI, Andrea;CIRIONI, OSCAR;SILVESTRI, Carmela;LICCI, ALBERTO;SCALISE, Giorgio
2005-01-01
Abstract
The in vitro activity of the histatin derivative P-113, alone or combined with eight antibiotics, was investigated against multidrug-resistant strains isolated from clinical specimens of immunocompromised patients with pneumonia. The gram-negative isolates were susceptible to P-113. S. aureus showed less susceptibility. Synergy was demonstrated when P-113 was combined with beta-lactams against gram-negative organisms.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
